ArticlePharmaceutical research2026
Immune Efficacy of a Vaccine Candidate Based on Binding Protein 26 (BP26) from Brucella melitensis Encapsulated in Niosome Nanoparticles Against Brucellosis.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBrucellosis is a common zoonosis, affecting animals and humans. Given the high prevalence of brucellosis, as well as the challenges associated with the animal vaccines, there is a need to develop effective vaccines against it. In this study, a Brucella vaccine candidate was developed based on niosome nanoparticles encapsulating BP26 protein from Brucella melitensis.
methodsCloning of amplified bp26 gene, cloning in pET28a-BL21 (DE3), and protein expression were done by optimized protocols. The properties of the synthesized niosome nanoparticles were evaluated using dynamic light scattering (DLS) and electron microscopy. Then, the entrapment efficacy, release profile, and effectiveness of BP26-encapsulated niosomes were assessed in vitro and in vivo.
resultsAnalyses indicated BP26-encapsulated niosomes with an average size of 265.5 nm, entrapment efficacy of 95.4%, and release rate of 27.4%. The BP26 encapsulated in niosome maintained the humoral immune responses up to 110 days after the initial vaccination in mice. Mice immunized with free BP26 and those receiving BP26.niosome had significantly higher levels of both IgG1 (Th2) and IgG2a (Th1) compared to the controls. In addition, mice vaccinated with niosome encapsulating BP26 produced higher IFN-γ and IL-2 cytokines as Th1 response indicators compared to BP26 alone, demonstrating the tendency of niosomes to switch the responses toward cellular immunity. Niosomes encapsulating BP26 could significantly protect the mice against Brucella melitensis.
conclusionsOur results suggest BP26-encapsulating niosome as a potential vaccine candidate for combating B. melitensis. However, further investigations are needed to present BP26.niosome as a promising Brucella vaccine for clinical trials.
Indexed as
Identifiers
42115561What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.